In line with this suggestion, recent animal studies demonstrated that blockade of HMGB-1 attenuates DN in streptozotocin induced diabetic rat and mice models, showing reducing albuminuria, glomerular injuries, interstitial fibrosis, and renal inflammation, although the association between HMBG-1 inhibition and functional changes in kidney DCs was not evaluated [81,82]. Here, HMGB1 is linked to liver dysplastic nodule.